Transcatheter aortic valve replacement during the COVID-19 pandemic-A Dutch single-center analysis
| Autor: | Helmut Gehlmann, Niels van Royen, Wilson W.L. Li, Laurens W. Wollersheim, Guillaume S.C. Geuzebroek, Michel W.A. Verkroost, Marleen H. van Wely, Leen van Garsse, Wim J. Morshuis, Heiman F. L. Wertheim, Maxim J.P. Rooijakkers |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Aortic valve Pulmonary and Respiratory Medicine medicine.medical_specialty medicine.medical_treatment Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Comorbidity 030204 cardiovascular system & hematology replacement Single Center law.invention Transcatheter Aortic Valve Replacement 03 medical and health sciences 0302 clinical medicine Valve replacement law Pandemic medicine Humans Pandemics Aged Netherlands Retrospective Studies Aged 80 and over SARS-CoV-2 business.industry Other Research Radboud Institute for Health Sciences [Radboudumc 0] COVID-19 Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16] Retrospective cohort study Original Articles Aortic Valve Stenosis valve repair medicine.disease Intensive care unit Treatment Outcome medicine.anatomical_structure lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] 030228 respiratory system Aortic Valve Aortic valve stenosis Emergency medicine Original Article Female Surgery business Cardiology and Cardiovascular Medicine |
| Zdroj: | Journal of Cardiac Surgery, 36, 48-55 Journal of Cardiac Surgery, 36, 1, pp. 48-55 Journal of Cardiac Surgery |
| ISSN: | 0886-0440 |
| Popis: | Contains fulltext : 235367.pdf (Publisher’s version ) (Open Access) BACKGROUND AND AIM OF THE STUDY: The coronavirus disease 2019 (COVID-19) pandemic has put an enormous strain on healthcare systems and intensive care unit (ICU) capacity, leading to suspension of most elective procedures, including transcatheter aortic valve replacement (TAVR). However, deferment of TAVR is associated with significant wait-time mortality in patients with severe aortic valve stenosis. Conversely, there is currently no data available regarding the safety and feasibility of a continued TAVR program during this unprecedented crisis. The aim of this study is to evaluate the safety and feasibility of patients undergoing TAVR during the COVID-19 pandemic in our center, with specific emphasis on COVID-19 related outcomes. METHODS: All patients who underwent TAVR in our center between February 27, 2020, and June 30, 2020, were evaluated. Clinical outcomes were described in terms of Valve Academic Research Consortium 2 definitions. Patient follow-up was done by chart review and telephone survey. RESULTS: A total of 71 patients have undergone TAVR during the study period. Median age was 80 years, 63% were men, and 25% were inpatients. Procedural success was 99%. After TAVR, 30% involved admission to the ICU, and 94% were ultimately discharged to the cardiac care unit on the same day. Two patients (3%) had confirmed COVID-19 a few days after TAVR, and both died of COVID-19 pneumonia within 2 weeks after hospital discharge. CONCLUSIONS: A continued TAVR program during the COVID-19 pandemic is feasible despite limited hospital resources. However, COVID-19 related mortality after TAVR is of concern. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|